More than 2,000 immune-oncology drugs now in development
pharma times | December 08, 2017
A new report has found that there are more than 2,000 immunotherapy drugs now in development for cancer, with 940 of these in clinical stage development and 1,064 at the preclinical stage. The report, “Comprehensive Analysis of the Immuno-Oncology Landscape” by the Cancer Research Institute (CRI), is a first-of-its-kind independent analysis of the global immuno-oncology landscape, from agents in pre-clinical development to regulatory approval. The report says that the significant number of immuotherapy agents in development will likely result in an unparalleled number of advances in the field—but it also creates some challenges.